Table 2.
Comparison of characteristics between non-survivors and survivors
| Characteristic | Non-Survivors (n=12) |
Survivors (n=62) |
p-value |
|---|---|---|---|
| Age, median (IQR), years | 2.0 (0.9–5.7) | 7.3 (1.9–14.7) | 0.05a |
| Male gender, n (%) | 7 (58%) | 28 (45%) | 0.4b |
| Prior Comorbidity, n (%) | 5 (42%) | 31 (50%) | 0.6b |
| Oncologic/Immunocompromised, n (%) | 1 (8%) | 10 (16%) | 0.49b |
| Initial lactate, median (IQR), mmol/L | 3.6 (2.0–9.0) | 2.3 (1.4–3.5) | 0.11a |
| Vasoactive use, n (%) | 9 (75%) | 29 (47%) | 0.07b |
| Mechanical Ventilation, n (%) | 10 (83%) | 26 (42%) | <0.01b |
| PRISM-III, median (IQR) | 19 (13.5–30.5) | 8 (3–12) | <0.001a |
| Day 1 PELOD, median (IQR) | 21.5 (11–26.5) | 11 (10–13) | <0.001a |
a
Wilcoxon rank sum,
b
Chi-square or Fisher exact